首页> 外文OA文献 >The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis.
【2h】

The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis.

机译:短突触核蛋白(促肾上腺皮质激素)刺激测试对下丘脑-垂体-肾上腺轴的评估的长期预测准确性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CONTEXT: The high-dose short Synacthen (corticotropin) test (SST) is widely used to investigate suspected secondary adrenal insufficiency, but concern remains about falsely reassuring results. OBJECTIVE: Our objective was to evaluate the long-term safety of the SST. METHOD: We retrospectively evaluated the clinical outcome in 178 patients who achieved 30-min cortisol values in the lowest 15th percentile of normal healthy responses. Thirty patients were later excluded because of missing case notes (20 patients) or unsubstantiated pituitary pathology (10 patients). The remaining 148 patients were divided into two groups: group 1, patients with cortisol response between the 5th and 15th percentiles of normal response (551-635 nmol/liter, 98 patients); and group 2, patients with borderline response between the 2.5th and 5th percentiles (510-550 nmol/liter, 50 patients). Patients did not receive routine glucocorticoid therapy, but those in group 2 were advised to take hydrocortisone in case of intercurrent illness. RESULTS: The median follow-up period from the initial SST was 4.2 yr (range, 4 months to 7 yr). A total of 137 patients showed no clinical or biochemical evidence of adrenal insufficiency during follow-up. Of the remaining 11 patients, seven became hypoadrenal after subsequent pituitary surgery or radiotherapy, one patient in group 1 developed adrenal insufficiency at 2 yr, and one patient in group 2 developed adrenal insufficiency at 6 months. The other two patients who were in group 2 had clinical diagnostic uncertainty. CONCLUSION: The high-dose SST is safe for the purpose of excluding clinically significant secondary adrenal insufficiency and is indicated as the first line of investigation for this purpose.
机译:背景:高剂量短促合成素(促肾上腺皮质激素)试验(SST)被广泛用于调查可疑继发性肾上腺皮质功能不全,但仍存在对令人误解的令人放心的结果的担忧。目的:我们的目的是评估SST的长期安全性。方法:我们回顾性评估了178例患者的临床结局,这些患者在正常健康应答的最低15%范围内达到30分钟的皮质醇值。后来由于缺少病例记录(20例)或垂体病理学不足(10例)而被排除的30例患者。其余148例患者分为两组:第1组,皮质醇反应在正常反应的第5个百分点与第15个百分点之间的患者(551-635 nmol /升,98例);第2组,边缘反应介于2.5%和5%之间的患者(510-550 nmol /升,50位患者)。患者未接受常规糖皮质激素治疗,但建议第2组患者在并发疾病时服用氢化可的松。结果:从最初的SST开始的中位随访期为4.2年(范围为4个月至7年)。共有137例患者在随访期间未显示肾上腺功能不全的临床或生化证据。在其余的11名患者中,有7名在随后的垂体手术或放疗后变为肾上腺皮质功能减退,第1组的一名患者在2年时出现肾上腺功能不全,而第2组的一名患者在6个月时出现肾上腺功能不全。第2组的其他两名患者具有临床诊断不确定性。结论:大剂量SST可以安全地排除临床上明显的继发性肾上腺皮质功能不全,并且被指示为该目的的第一线研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号